The abstract is read at the publisher; the summary is JClub's.
In compensated chronic hepatitis D, bulevirtide monotherapy for 144 weeks produced end-of-treatment virologic response rates of 73% (2 mg), 76% (10 mg), and 92% (DT/10), with post-treatment decline.
- Why it matters: Long-term outcomes after stopping bulevirtide in compensated chronic hepatitis D are unknown, limiting guidance on how durable responses are beyond 2 years and after discontinuation.
- What they did: In MYR301 (NCT03852719), 150 randomized patients received bulevirtide 2 mg/day, 10 mg/day, or delayed treatment (48W delay then 10 mg/day) for 144W, followed by 96W post-treatment follow-up.
- The result: At FU96, virologic response fell to 33%, 30%, and 32%, while HDV RNA undetectability was 20%, 22%, and 20%; sustained undetectability occurred in 23/64 (36%) with EOT undetectability, and post-treatment hepatic serious adverse events were 14% (resolved in 85%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.